VCEL (Vericel Corporation) Utang jangka cendhak marang modal

Logo korporat perusahaan Vericel Corporation (VCEL)

Vericel Corporation (VCEL) is developing cellular restoration methods for skin and cartilage, utilizing two marketed products to ensure revenue stability. The price action vector available for analysis on GURU.Markets with the 0.05 indicator confirms the potential of this regenerative medicine. Vericel Corporation (VCEL) creates tissues from a patient's own cells by implementing advanced engineering. The business is currently scaling sales by expanding its sales representative workforce across the United States.

Rasio tanggungan utang jangka cendhak marang modal: Vericel Corp. (VCEL) kanggo 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Vericel Corporation

- kuotasi lan prakiraan analis:
Rega saham Vericel Corp.|VCEL - Konsensus nilai wajar
- indikator valuasi pasar bisnis:
Kapitalisasi pasar Vericel Corp|VCEL - Nilai Perusahaan
- informasi kapitalisasi buku:
Aset Bersih saben Siji Saham Vericel|VCEL - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku vcel.com|VCEL - Gunggung Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Vericel Corporation|VCEL - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Vericel|VCEL - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Vericel Corp|VCEL - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Vericel|Rasio cepet vcel.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
VCEL - Asil keuangan resik
Pambiji fundamental:VCEL Vericel Corp.
Produk merek Vericel Corp

Steady sales growth of cellular products and management discipline at Vericel Corporation (VCEL) enable effective control of the current debt load. By analyzing the ratio of short-term liabilities to equity, an investor assesses the share of short-term loans within the equity structure, where a decrease in this metric confirms growing financial autonomy and an expanded margin of safety for the company's assets.

Pesaing utama

Utang jangka cendhak marang modal KRYS|APGE (Apogee Corp) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal ARQT (Arcutis Biotherapeutics)|Utang jangka cendhak marang modal orukatx.com ORKA|SMTI - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal DBVT (DBV Technologies S.A.)|solesence.com (SLSN) - Utang jangka cendhak marang ekuitas|Rasio utang jangka cendhak marang ekuitas Journey Medical Corporation|FBRX (Forte Biosciences, Inc.) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal empro.my|Rasio utang jangka cendhak marang ekuitas SLGL (Sol-Gel Technologies Ltd.)|AXIL (reviveprocare.com) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Medicus Pharma Limited MDCX|Koefisien utang jangka cendhak marang modal Verrica Pharmaceuticals Inc (VRCA)|HOTH - Utang jangka cendhak marang ekuitas|BFRI - Utang jangka cendhak marang modal|VYNE: Utang jangka cendhak marang modal|SNOA - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Quoin Pharmaceuticals Ltd|Rasio utang jangka cendhak marang modal AZTR (Azitra Corporation)|Rasio utang jangka cendhak marang ekuitas DRMA (Dermata Therapeutics)|Utang jangka cendhak marang ekuitas ELAB (elevaiskincare.com)|Utang jangka cendhak marang modal RVNC (Revance Therapeutics, Inc.)